Qualis/CAPES  B4 (2017-2020) Google Scholar   Citations: 754   |   h‑index: 12   |   i10‑index: 20   |   h5‑index: 56   |   h5‑median: 8 Impact Factor  SJIF: 3.138 (2021)
Budgetary impact of incorporating clarithromycin in the treatment of respiratory infection associated with COVID-19
PDF (Português (Brasil))
PDF

Keywords

Pandemic
COVID-19
Unified Health System
Budgetary Impact Analysis
Drug Therapy

How to Cite

1.
Maia Pessanha C, Barbosa Meireles I, Coura C, Batista de Souza J, de Freitas Peregrino AA, Lyra Silva RC. Budgetary impact of incorporating clarithromycin in the treatment of respiratory infection associated with COVID-19. Glob Acad Nurs [Internet]. 2021 Sep. 15 [cited 2024 May 11];2(Spe.2):e107. Available from: https://globalacademicnursing.com/index.php/globacadnurs/article/view/210

Abstract

This study aimed to estimate the budgetary impact of using clarithromycin as a supporting macrolide in the empirical treatment scheme for patients with Severe Acute Respiratory Syndrome. Budget impact analysis was carried out from the perspective of the Unified Health System, using the Brazilian Budget Impact Analysis Worksheet. Three alternative scenarios and one reference scenario were evaluated. The cost over five years in the baseline scenario was R$2,504,887.92. The incorporation of clarithromycin in alternative scenarios may represent an average incremental cost greater than 22% of the budget available for the acquisition of azithromycin in five years, and its offer to all patients in the hospital may be economically unfeasible, without prejudice to the care of other demands.

https://doi.org/10.5935/2675-5602.20200107
PDF (Português (Brasil))
PDF

References

Faria MGA, Fonseca CSG. Pandemia de COVID-19 e de desinformação: um panorama do Brasil. Glob Acad Nurs. 2020;1(1):e1.doi: https://dx.doi.org/10.5935/2675-5602.20200001

Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Protocolo de tratamento de Influenza: 2017 [Internet]. Brasília: Ministério da Saúde; 2018. [acesso em 01 jun. 2020]. 49 p. Disponível em: <http://bvsms.saude.gov.br/publicacoes/protocolo_tratamento_influenza_2017>. Acesso em: 01 de junho de 2020.

Ministério da Saúde (BR). Secretaria de Atenção Especializada à Saúde. Departamento de Atenção Hospitalar, Domiciliar e de Urgência. Protocolo de manejo clínico da Covid-19 na Atenção Especializada [Internet]. Brasília: Ministério da Saúde; 2020. [acesso em 27 maio 2020]. 48p. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/manejo_clinico_covid-19_atencao_especializada.pdf>. Acesso em: 01 de junho de 2020.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506.

Spernovasilis N, Kofteridis D. COVID-19 and antimicrobial stewardship: What is the interplay? Infection Control & Hospital Epidemiology. 2020;1–6.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061–1069.

Corrêa R de A, Costa AN, Lundgren F, Michelin L, Figueiredo MR, Holanda M, et al. 2018 recommendations for the management of community acquired pneumonia. Jornal Brasileiro de Pneumologia. 2018;44(5):405–423.

Rae N, Singanayagam A, Schembri S, Chalmers JD. Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study. Pneumonia. 2017;9(1):2.

LeBel M. Pharmacokinetic properties of clarithromycin: A comparison with erythromycin and azithromycin. Canadian Journal of Infectious Diseases. 1993;4.

Newton PN, Bond KC, Adeyeye M, Antignac M, Ashenef A, Awab GR, et al. COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. The Lancet Global Health. 2020;8(6):e754–e755.

Hopman J, Allegranzi B, Mehtar S. Managing COVID-19 in low-and middle-income countries. Jama. 2020;323(16):1549–1550.

Choo EK, Rajkumar SV. Medication shortages during the COVID-19 crisis: what we must do. In: Mayo Clinic Proceedings. Elsevier; 2020. p. 1112–1115.

Mazer-Amirshahi M, Fox ER, Farmer BM, Stolbach AI. ACMT Position Statement: Medication Shortages During Coronavirus Disease Pandemic. Journal of Medical Toxicology. 2020;1.

Ministério da Saúde (BR). Secretaria de Ciência e Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes de avaliação econômica. Brasília: Ministério da Saúde, 4ª. Ed. 2014.

Novaes HMD, Soárez PC de. Health technology assessment (HTA) organizations: dimensions of the institutional and political framework. Cadernos de saude publica. 2016;32:e00022315.

Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: análise de impacto orçamentário: manual para o Sistema de Saúde do Brasil [Internet]. Brasília: Ministério da Saúde; 2012. [acesso em 30 maio 2020]. 76 p. Disponível em: http://rebrats.saude.gov.br/diretrizes-metodologicas

Gadelha CAG, Costa LS, de Varge Maldonado JMS, Barbosa PR, Ant M, others. The health care economic-industrial complex: Concepts and general characteristics. Health. 2013;2013.

Painel de Preços [Internet]. Brasília, DF: Ministério da Economia. [acesso em 15 maio 2020]. Disponível em: https://paineldeprecos.planejamento.gov.br/analise-materiais.

Ministério da Saúde (BR). Secretaria de Atenção Especializada à Saúde. Portaria nº 237, de 18 de março de 2020. Inclui leitos e procedimentos na Tabela de Procedimentos, Medicamentos, Órteses, Próteses e Materiais Especiais (OPM) do Sistema Único de Saúde (SUS), para atendimento exclusivo dos pacientes com COVID-19. Diário Oficial da União, Brasília, DF, 20 mar. 2020. Edição 55, Seção 1, p. 206.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2021 Global Academic Nursing Journal

Downloads

Download data is not yet available.